TY - JOUR
T1 - Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations
T2 - Clinical, pathological, and family characteristics
AU - Zuradelli, Monica
AU - Peissel, Bernard
AU - Manoukian, Siranoush
AU - Zaffaroni, Daniela
AU - Barile, Monica
AU - Pensotti, Valeria
AU - Cavallari, Ugo
AU - Masci, Giovanna
AU - Mariette, Frederique
AU - Benski, Anne Caroline
AU - Santoro, Armando
AU - Radice, Paolo
PY - 2010/11
Y1 - 2010/11
N2 - Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.
AB - Double heterozygosity (DH) for BRCA1 and BRCA2 mutations is a very rare finding, particularly in non-Ashkenazi individuals, and only a few cases have been reported to date. In addition, little is known on the pathological features of the tumors that occur in DH cases and on their family history of cancer. Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions. Clinical, pathological, and family history data were collected from medical records and during genetic counseling sessions. All identified DH cases developed breast carcinoma and three of them were also diagnosed with ovarian carcinoma. Mean ages of breast and ovarian cancer diagnosis were 42.7 and 48.6 years, respectively. The majority of breast cancers showed a BRCA1-related phenotype, being negative for hormone receptors and HER2. Two cases reported different gastrointestinal tumors among relatives. Although the individuals described in this study show more severe clinical features in comparison to previously reported BRCA1 and BRCA2 DH cases, our observations support the hypothesis of a non specific phenotype of DH cases in terms of age of disease onset. In addition, our observations indicate that in DH patients breast carcinogenesis appears to be driven mainly by the mutations in BRCA1. The possible association of DH for BRCA gene mutations with gastrointestinal tumors is in keeping with previous reports, but needs to be confirmed by further analyses.
KW - BRCA1
KW - BRCA2
KW - Cancer susceptibility
KW - Double heterozygosity
KW - Genetic counseling
UR - http://www.scopus.com/inward/record.url?scp=77957714920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957714920&partnerID=8YFLogxK
U2 - 10.1007/s10549-010-0853-8
DO - 10.1007/s10549-010-0853-8
M3 - Article
C2 - 20373018
AN - SCOPUS:77957714920
SN - 0167-6806
VL - 124
SP - 251
EP - 258
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -